

# **BIOCON GROUP**

**FY2010 vs. FY 2009**  
**Q4 FY 2010 vs Q4 FY 2009**

## **FACT SHEET**

<b>BIOCON LIMITED (CONSOLIDATED)</b>		
<b>BALANCE SHEET</b>		(Rs. Crores)
<b>Particulars</b>	<b>As at 31-Mar-10</b>	<b>As at 31-Mar-09</b>
<b><u>SOURCES OF FUNDS</u></b>		
Share Capital	100	100
Reserves & Surplus	1,658	1,411
<b>Total Shareholder's Funds</b>	<b>1,758</b>	<b>1,511</b>
<b>Minority interest</b>	<b>34</b>	<b>25</b>
<b>Deferred Tax Liability</b>	<b>51</b>	<b>47</b>
Secured Loans	332	396
Unsecured Loans	182	128
<b>Total Loan Funds</b>	<b>514</b>	<b>524</b>
<b>Total</b>	<b>2,356</b>	<b>2,106</b>
<b><u>APPLICATION OF FUNDS</u></b>		
<b>Fixed Assets (Net)</b>	<b>1,244</b>	<b>1,221</b>
<b>Intangible Assets</b>	<b>170</b>	<b>163</b>
<b>Investments</b>	<b>431</b>	<b>368</b>
Inventories	372	319
Sundry debtors	446	367
Cash and bank balances	140	12
Loans and advances	134	95
<b>Total Current Assets, Loans &amp; Advances</b>	<b>1,092</b>	<b>792</b>
<b>Less: Current liabilities and provisions</b>	<b>580</b>	<b>438</b>
<b>Net Current assets</b>	<b>512</b>	<b>355</b>
<b>Total</b>	<b>2,356</b>	<b>2,106</b>

**BIOCON LIMITED (CONSOLIDATED)**  
**PROFIT & LOSS STATEMENT**

(Rs. Crores)

Particulars	WITH AXICORP	WITH AXICORP	Variance	WITHOUT AXICORP	WITHOUT AXICORP	Variance
	FY 10	FY 09		FY 10	FY 09	
<b><u>INCOME</u></b>						
Biopharmaceuticals	2,087	1,384	51%	1,180	915	29%
Contract research	281	225	25%	281	225	25%
<b>Total Sales</b>	<b>2,368</b>	<b>1,609</b>	<b>47%</b>	<b>1,461</b>	<b>1,139</b>	<b>28%</b>
Other income	37	65	-43%	32	54	-40%
<b>Total Income / Revenues</b>	<b>2,405</b>	<b>1,673</b>	<b>44%</b>	<b>1,493</b>	<b>1,194</b>	<b>25%</b>
<b><u>EXPENDITURE</u></b>						
Material & Power Costs	1,405	908	55%	681	516	32%
Staff costs	229	168	36%	159	129	23%
Research & Development	78	60	31%	78	60	31%
Forex Loss/ (gain)	6	11	-47%	6	11	-47%
Other Expenses	178	139	28%	114	107	7%
<b>Manufacturing, staff &amp; other exps</b>	<b>1,896</b>	<b>1,285</b>	<b>48%</b>	<b>1,038</b>	<b>822</b>	<b>26%</b>
<b>PBDIT /EBIDTA</b>	<b>509</b>	<b>388</b>	<b>31%</b>	<b>455</b>	<b>372</b>	<b>22%</b>
Interest and finance charges	17	18	-5%	15	15	-4%
<b>PBDT</b>	<b>492</b>	<b>370</b>	<b>33%</b>	<b>440</b>	<b>356</b>	<b>24%</b>
Depreciation	140	110	27%	135	108	26%
<b>PBT</b>	<b>352</b>	<b>260</b>	<b>35%</b>	<b>305</b>	<b>248</b>	<b>23%</b>
Taxes	49	12		32	10	
<b>PROFIT FOR THE PERIOD</b>	<b>303</b>	<b>248</b>	<b>22%</b>	<b>273</b>	<b>238</b>	<b>14%</b>
Add/(less): Minority interest / Share of Losses in Associates	(10)	(8)	21%	(3)	(5)	0%
<b>Profit before Exceptional Items</b>	<b>293</b>	<b>240</b>	<b>22%</b>	<b>270</b>	<b>234</b>	<b>15%</b>
<b>Exceptional Item - Net of Tax</b>	<b>0</b>	<b>(147)</b>		<b>0</b>	<b>(147)</b>	
<b>NET PROFIT (PAT)</b>	<b>293</b>	<b>93</b>	<b>215%</b>	<b>270</b>	<b>87</b>	<b>211%</b>
<b>EPS on issued capital Rs. (before exceptional items)</b>	<b>14.7</b>	<b>12.0</b>		<b>13.5</b>	<b>11.7</b>	

Note: The figures are rounded off to the nearest million, percentages are based on absolute numbers

Biopharmaceuticals includes licensing income of Rs 51 Crores for FY2010, Rs 12 Crores in FY2009 (both with and without Axicorp);

**BIOCON LIMITED (CONSOLIDATED)**  
**PROFIT & LOSS STATEMENT**

(Rs. Crores)

Particulars	Q4	Q4	Variance	Q4	Q4	Variance
	WITH AXICORP FY 10	WITH AXICORP FY 09		WITHOUT AXICORP FY 10	WITHOUT AXICORP FY 09	
<b>INCOME</b>						
Biopharmaceuticals	583	398	46%	334	224	49%
Contract research	74	68	9%	74	68	9%
<b>Total Sales</b>	<b>657</b>	<b>466</b>	<b>41%</b>	<b>408</b>	<b>292</b>	<b>40%</b>
Other income	9	20	-57%	7	12	-47%
<b>Total Income / Revenues</b>	<b>666</b>	<b>487</b>	<b>37%</b>	<b>415</b>	<b>304</b>	<b>36%</b>
<b>EXPENDITURE</b>						
Material & Power Costs	398	279	42%	202	131	54%
Staff costs	60	45	35%	42	32	33%
Research & Development	19	20	-5%	19	20	-5%
Forex Loss/ (gain)	4	(5)	-187%	4	(5)	-181%
Other Expenses	45	37	21%	20	25	-20%
<b>Manufacturing, staff &amp; other exps</b>	<b>526</b>	<b>376</b>	<b>40%</b>	<b>288</b>	<b>203</b>	<b>42%</b>
<b>PBDIT /EBIDTA</b>	<b>139</b>	<b>110</b>	<b>26%</b>	<b>127</b>	<b>102</b>	<b>25%</b>
Interest and finance charges	3	6	-46%	3	5	-46%
<b>PBDT</b>	<b>136</b>	<b>104</b>	<b>31%</b>	<b>124</b>	<b>96</b>	<b>29%</b>
Depreciation	37	31	20%	35	30	19%
<b>PBT</b>	<b>99</b>	<b>73</b>	<b>35%</b>	<b>89</b>	<b>67</b>	<b>33%</b>
Taxes	14	(2)		9	(2)	-680%
<b>PROFIT FOR THE PERIOD</b>	<b>85</b>	<b>75</b>	<b>13%</b>	<b>80</b>	<b>68</b>	<b>18%</b>
Add/(less): Minority interest / Share of Losses in Associates	(4)	(9)		(3)	(7)	0%
<b>Profit before Exceptional Items</b>	<b>81</b>	<b>66</b>	<b>22%</b>	<b>77</b>	<b>62</b>	<b>25%</b>
<b>Exceptional Item - Net of Tax **</b>	<b>0</b>	<b>(41)</b>		<b>0</b>	<b>(41)</b>	
<b>NET PROFIT (PAT)</b>	<b>81</b>	<b>25</b>	<b>224%</b>	<b>77</b>	<b>20</b>	<b>280%</b>
<b>EPS on issued capital Rs. (before exceptional items)</b>	<b>4.0</b>	<b>3.3</b>		<b>3.9</b>	<b>3.1</b>	

Note: The figures are rounded off to the nearest million, percentages are based on absolute numbers

Biopharmaceuticals includes licensing income of Rs 21 Crores in Q4 FY2010, Rs 6 Crores in Q4 FY2009 (both with and without Axicorp);